Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.
about
Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart DiseaseRespiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review.Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infantsLong-Term Burden and Respiratory Effects of Respiratory Syncytial Virus Hospitalization in Preterm Infants-The SPRING StudyPredictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI).Preventing hospitalizations for respiratory syncytial virus infectionEffects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation.The Burden of Severe Respiratory Syncytial Virus Disease Among Children Younger than 1 Year in Central and Eastern Europe.Burden of Severe Respiratory Syncytial Virus Disease Among 33-35 Weeks' Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons.Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention.Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States.The impact of commercial rapid respiratory virus diagnostic tests on patient outcomes and health system utilization.Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis.Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.Statistical Power to Detect an Association Between Guideline-based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus InfectionsModeling the Potential Impact of the 2014 American Academy of Pediatrics Respiratory Syncytial Virus Prophylaxis Guidance on Preterm Infant RSV Outcomes.Perceived Risk of Severe Respiratory Syncytial Virus Disease and Immunoprophylaxis Use Among US Pediatric Specialists.Insurance Status and the Risk of Severe Respiratory Syncytial Virus Disease in United States Preterm Infants Born at 32-35 Weeks Gestational Age.RSV infection among children born moderately preterm in a community-based cohort.The Outpatient Burden of Respiratory Syncytial Virus Infections in Older Children.Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants.Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants.Prévenir les hospitalisations pour l’infection par le virus respiratoire syncytial.Risk factors for bronchiolitis severity: A retrospective review of patients admitted to the university hospital from central region of Slovenia
P2860
Q28072535-30400C88-F6E0-49A3-96A9-C7E83F52CA52Q30251560-990FAB95-5FDD-4235-B52A-3FAC8C26EBFCQ31047460-D6ACB9FC-FFDB-4EF0-8D13-CE828EE63DDFQ35587298-EDA44C79-34AA-4FBE-90F0-9A3C4A8E2858Q36054311-ECD557BB-4889-4ADD-AAA4-B3E5A069442FQ36082195-D1FF2E51-C018-4D1E-A275-141115059725Q36206766-E807C5E2-E892-4FA1-9957-2099450C8D75Q37056532-944F0A00-3975-4ED4-8EB9-F1A7C0ACE125Q37591891-860B6E06-9503-43A2-812E-20F90BF9532BQ38604949-DB65695C-4D8E-4247-8960-0C2FE73DF3CDQ40060039-DCA23F5A-8E14-40BA-B8A0-2578CEB24297Q40070238-466B1E12-D2A3-407E-82BA-59CCD2EFFB79Q40122511-A3D655FE-24BD-4988-8151-D1C95B32B9A1Q40251705-C92261F3-3A13-4FDE-A408-2C2A3F4184ADQ40337141-D6C9F706-E802-4F17-BD19-423FA3BE4E56Q40395412-7D54B58F-EDF8-478B-9D4A-2ACBC24A30EDQ40508352-215F8C02-3693-474D-9DCD-2C194D68965DQ40516621-9F66C502-6BA3-4B81-8D72-98BCEAE158CCQ41753179-F2CFD498-2706-447C-A547-59B3B27F9265Q45332698-E4F5E0BE-57F9-4EFD-8AB4-BD3806585A9DQ48098961-40BEE09B-F18C-45E5-ADB8-2522186B0424Q49720574-5FF2B11B-7118-4B67-A943-CD34DAB44DB6Q53932344-CEEC190E-3456-45F2-A1CF-ACD7F0AA030CQ58791847-AC7B3E7A-AD7B-40E0-80BA-DD9DDEFC85B4
P2860
Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Respiratory syncytial virus di ...... t receiving immunoprophylaxis.
@ast
Respiratory syncytial virus di ...... t receiving immunoprophylaxis.
@en
type
label
Respiratory syncytial virus di ...... t receiving immunoprophylaxis.
@ast
Respiratory syncytial virus di ...... t receiving immunoprophylaxis.
@en
prefLabel
Respiratory syncytial virus di ...... t receiving immunoprophylaxis.
@ast
Respiratory syncytial virus di ...... t receiving immunoprophylaxis.
@en
P2093
P2860
P1476
Respiratory syncytial virus di ...... ot receiving immunoprophylaxis
@en
P2093
C Lucy Park
Eric A F Simões
Evan J Anderson
Frangiscos Sifakis
Hanaa Elhefni
Jessie R Groothuis
Xionghua Wu
P2860
P304
P356
10.1097/INF.0000000000000219
P577
2014-06-01T00:00:00Z